Fan, Yuru
Zhang, Xuan
Zhang, Qin
Zheng, Liang
Zhou, Renpeng
Sun, Cheng
Wang, Xihan
Song, Ke
He, Zhusheng
Wang, Honghui
Zhang, Qian
Clinical trials referenced in this document:
Documents that mention this clinical trial
Safety and Pharmacokinetics of HRS-2261, a P2X3 Receptor Antagonist, in Healthy Subjects: A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study
https://doi.org/10.1007/s40262-023-01330-7
Funding for this research was provided by:
Jiangsu Hengrui Medicine
Article History
Accepted: 14 November 2023
First Online: 10 January 2024
Declarations
:
: This study was supported by Jiangsu Hengrui Pharmaceuticals Co., Ltd.
: XW, KS, ZH, and HW are employees of Jiangsu Hengrui Pharmaceuticals Co., Ltd. Other co-authors declare no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice Guideline. Study protocol and all amendments were approved by the independent ethics committee of The Second Affiliated Hospital of Anhui Medical University. All subjects provided written informed consent before enrollment.
: Not applicable.
: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.
: QianZ, WH, and HW were responsible for the conception and design of the study. YF, XZ, QinZ, LZ, RZ, CS, XW, ZH, HW, QianZ, and WH contributed to the data collection. KS was responsible for the statistical analysis. All authors read and approved the final manuscript.